Friday, August 28, 2009


Early and aggressive selling early in the Thursday session was met by even more aggressive buying later in the day, keeping a number of ETFs from retreating into overbought territory.

Here are 7 ETFs You Need to Know for Friday.

From a sector perspective, buyers were most interested in financial shares on Thursday, making the Financial Select Sector SPDRS ETF (XLF | Quote | Chart | News | PowerRating) among the better performing sector SPDRS on the day. Up over 1% was the ProShares Ultra Financials ETF (UYG | Quote | Chart | News | PowerRating).

After moving lower for three consecutive trading days, basic materials ETFs like the iShares Dow Jones Basic Materials Sector Index ETF (IYM | Quote | Chart | News | PowerRating) staved off early selling to close higher on the day.

Among the country ETFs that are still oversold above the 200-day moving average, the iShares MSCI Hong Kong Index ETF (EWH | Quote | Chart | News | PowerRating) lost well over 1% on Thursday before rallying later in the session.

Up nearly 1% late in the day was the CurrencyShares Euro Trust ETF (FXE | Quote | Chart | News | PowerRating). FXE was among the currency ETFs that we highlighted early in the week as oversold in 7 ETFs You Need to Know for Today. Also gaining significantly against the dollar was the CurrencyShares Japanese Yen Trust ETF (FXY | Quote | Chart | News | PowerRating)

Late strength in stocks had produced late weakness in bonds. This has meant lower levels for bond ETFs like the iShares iBoxx Investment Grade Corporate Bond ETF (LQD | Quote | Chart | News | PowerRating) which darted toward oversold territory above the 200-day moving average.


Dire news from the FDIC advising that the bank insurance fund is down 20% in the 2nd quarter failed to frighten the stock bulls. Shares surged higher turning positive in a late day rally marking the 8th straight gain for the market. Natural gas and oil climbed while the U.S. Dollar slipped further against other major currencies. The DJIA gained 37.11, the tech heavy Nasdaq advanced 3.30 and the broad based S&P 500 eased higher by 2.86.

Here are 7 stocks you need to know for Friday.

Noted Jeweler Tiffany (TIF | Chart | News | PowerRating) has investors expecting an EPS of 33 cents for the second quarter 2010. TIF will announce before the bell on Friday morning.

Ex CEO Hank Greenberg is being consulted by the current Regime at American International Group (AIG | Chart | News | PowerRating).

An EPS loss of 30 cents is forecast for the fiscal third quarter 2009 by the Shiloh (SHLO | Chart | News | PowerRating) Industries Friday before the open.

Anti monopoly investigations have begun against wireless providers AT&T (T | Chart | NewsPowerRating) and Verizon (VZ | Chart | News | PowerRating). |

The third quarter 2009 has the Bank of Nova Scotia (BNS | Chart | News | PowerRating) looking for an EPS of 74 cents during the trading day on Friday.

Goldman Sachs (GS | Chart | News | PowerRating) has been subpoenaed by regulators due to its tradition of having weekly meetings between analysts and traders.

Watch List for Friday 8-28-2009-CHB,CBOE,PPTO

PPTO - Possible Bounce
Precision Petroleum Corporation is an independent energy company engaged in the acquisition, exploration and development of oil and natural gas properties in North America.

CHB - Break Out
Champion Enterprises, Inc., together with its subsidiaries, produces and sells factory-built housing in the United States and western Canada.

GBOE - Volume Alert
GeoBio Energy, Inc., a development stage company, operates as a biodiesel supply and distribution company in the United States.

Wednesday, August 26, 2009

5 PowerRatings Stocks for Today


7 Stocks You Need to Know for Today

Here are 7 stocks for traders for today from

Helix Wind Announces Joint Venture to Provide Finance

26th August 2009 - Helix Wind


Joint Venture with Atoll Financial Group Will Also Provide Short-Term and Trade Finance to Helix Wind Distributors

San Diego, CA – August 26, 2009 – Helix Wind Corp. (OTCBB: HLXW), a global renewable energy company, announced today that it has established a joint venture with Atoll Financial Group (AFG), Washington, DC, to offer individuals, small businesses, commercial users and its distributors’ financing of its small wind turbines.

Helix Wind CEO Ian Gardner said, “We are excited to be the only small wind company to offer individuals and small businesses financing for small wind turbines, which will make purchasing renewable energy substantially more affordable.” Under the terms of the joint venture,Helix Wind will finance turbines for distributors and end users on both a wholesale and retail basis.

The program will provide financing to individuals, businesses, commercial users of volume orders as well as short-term and trade finance to distributors. The benefit for individuals and small businesses is a smaller cash outlay and the ability to match expenditure with their electric bill savings. For commercial users with aggressive pay-back periods, the financing will also create cash flow. Importantly, Helix Wind distributors will be able to purchase and carry inventory. This will greatly minimize turnaround time for customers and help the company's distributors manage cash flows.

The arrangement will also enable Helix Wind to build manufacturing facilities, if needed, in those markets where demand supports the investment as well as finance export sales into countries were Helix Wind does not yet have a local partner.

Finally, Helix Wind will offer financing to Energy Services Companies (ESCO) and Renewable Energy Services (RESCO) companies. ESCO’s and RESCO’s provide discounted energy services to commercial end users under Power Purchase Agreements or leasing models. Providing needed financing to ESCO’s and RESCO’s will help deliver increased energy savings to their customers and drive adoption of Helix Wind’s technology.

“This joint venture with Atoll Financial Group provides Helix Wind with the operational flexibility we need to grow. Being able to offer financing to our customers is a significant accomplishment,” Gardner said.
About Atoll Financial Group:
A Washington, DC-based financial services company, Atoll Financial Group specializes in assisting public and privately owned corporations in raising funds in the capital market for the realization of long-term, multi-million dollar projects. For more information:

About Helix:
Helix Wind is a global renewable energy company. Helix Wind is engaged in the design, manufacturing and sale of small wind vertical axis turbine designed to generate 300W, 1kW, 2.0kW, 4.0kW, and 50kW of clean, renewable electricity. Additional information can be found at

Market close report for 8-25-09-Corn,Soybeans,Wheat,Cattle,Hogs,Cotton

Close - August 25, 2009

Corn prices closed lower and a dime off today's high price.
Basis bids for corn improved with several terminals 5 to 25
cents better earlier today. Gradual improvement over the
past couple of weeks on the crop conditions report supports
USDA projections of a bumper corn crop. Cooler than normal
weather is in the forecast through September 9th and could
delay crop development in the eastern Corn Belt and/or North
Dakota. Texas raises about 2% of the US corn production and
hot/dry weather has left southern Texas with a poor quality
corn crop according to the progress report this week.
Forecasts for the August 30th to September 3rd period show
Texas getting much needed rain in the drought stricken
central and southern portion of the state. The timing is
unfortunate, however, as producers in the southern portion
of Texas are already well along harvesting corn. September
Corn at $3.21 ½, down 8 cents December Corn at $3.26 ¾, down
8 ¾ cents

September Soybeans finished higher testing the high that was
made on August 13th earlier in the session at $11.08. New
crop soybeans were lower. The decline in new crop prices was
attributed to crop improvement on yesterday's progress
report and ideas there will be enough time to mature the
crop before the fall frost hits. Temperatures this season
have averaged below normal for much of the growing season in
many states so far this year. Above normal precipitation in
the Delta states, forecast from August 30th to September
3rd, will prevent some of the mature crop in that area from
drying down as harvest approaches. Louisiana is already
harvesting in some areas. The September soybean meal did
close above earlier highs made this month and also closed
above the July highs but December contracts forward closed
lower following the decline in new crop soybeans. All months
of soybean oil were lower due to weakness in diesel.
September Soybeans at $10.91, up 11 cents November Soybeans
at $9.99, down 8 ½ cents September Soy meal at $358.00, up
11.80 points September Soy oil at 36.54 cents, down 57

Wheat futures finished mixed with the CBOT and MGEX slightly
lower and the KCBT wheat slightly higher but the wheat on
all exchanges closed on the lower end of the day's trading
range. Wheat had been 15 to 17 higher at one point today.
Japan's planned purchase of food grade wheat that included
Hard Red Winter kept the KCBT wheat firmer. Japan increased
their normal tender from 126,000 MT to 160,000 MT. Gulf
basis bids for August and September are 4 to 2 cents better
for CBOT wheat. Egypt is in the market for wheat to be
delivered the last week of September from optional origin.
According to the KCBT Cash Grain Committee protein premiums
are being paid for 12.2% to 14% protein. Premiums up to 60
to 75 cents are offered for 14% protein. September CBOT
Wheat at $4.71, down ¾ cent September KCBT Wheat at $5.04 ¾,
up 1 ½ cents September MGEX Wheat at $5.36 ¼, down 1 ¾ cents

Live Cattle futures closed steady to slightly higher. Boxed
beef prices were higher this afternoon on light demand and
offerings. Choice beef closed at $143.73, up .70 and Select
finished at $136.99, up 1.13. Monday saw a few numbers trade
in the five area direct cattle regions with prices averaging
$82.43 for Steers and $82.00 for Heifers for all grades on
the live basis. The Oklahoma City Feeder Cattle auction
exhibited moderate demand for feeder cattle and good demand
for calves. The supply included 77% over 600 pounds and 34%
heifers. Recent rains and cooler temperatures have grass
pastures in very good condition. Yesterday's crop progress
report showed 21% poor/very poor, a one point improvement
from last week and 52% good/excellent, a 2 point improvement
from last week. August Live Cattle at $85.45, up 27 cents
August Feeder Cattle at $99.95, down 15 cents

Lean Hogs prices closed higher trading inside yesterday's
price range. Pork prices were higher across the board to
support the futures, with light to moderate demand and
offerings. Carcass prices at 56.37, up 2.51, Loins at 65.76,
up .17, Butts at 59.74, up 1.89, Picnics at 38.92, up 3.80,
Ribs at 93.57, up 1.54, Hams at 56.18, up 7.11, and Bellies
at 57.64, unchanged. Iowa/Minnesota weighted average price
was $46.34 Monday. The Lean Hog Index closed at 49.21, down
.11 for August 21st. Total open interest was up 2,171
contracts on yesterday's drop in prices indicating possible
new shorts. Cash terminal hogs were steady to lower. October
Lean Hogs at $48.30, up 147 cents December Lean Hogs at
$47.10, up 110 cents

Cotton futures finished the day lower breaking to the
downside of the channel formation formed over the past six
trading sessions. Friday's cotton volume was 5,820 contracts
with 126,580 contracts in open interest. Rains coming into
West Texas this week should benefit the cotton crop. The
cotton crop was rated 19% poor/very poor, a two point
deterioration and 62% good/excellent, a 1 point
deterioration from last week. China's economic recovery
could stimulate purchase of US cotton. Global cotton
production has been declining recently in China, Brazil and
the US. India is picking up the slack somewhat with
increased production forecast in the August USDA WASDE
report. Conditions are generally favorable for cotton
development in central China even though they have had heavy
rains recently in some areas. The Indian monsoons have been
spotty but the cotton crop is apparently doing ok. The DJIA
made new five month highs but closed in the lower portion of
the daily range. The US Do llar Index is slightly higher.
October Cotton at 55.97 cents, down 95 points December
Cotton at 58.15 cents, down 92 points

VNTA is in our Crosshairs

VNTA (Ventana Biotech) was up another 5% today on nice volume!!! We still feel that Wall Street is still buzzing about VNTA. We started profiling the company back on July 26 th for the first time and were able to see monster returns since then.

But the reason we are so excited about this VNTA this week is because we have been told that the same PR group that provided market and product awareness for CGCA (Cobra Oil and Gas) will be providing awareness and product recognition for VNTA.

The last major PR on CGCA involved thousands of investors pouring hundreds of thousands of dollars into a company that MIGHT one day find oil. What do you think will happen when all those investors are introduced to a company that has a product that will be rolled out in a multibillion dollar industry?

Today we saw BONU & CGCA, two of our recent alerts explode north on insane volume. Fortunately, some of our members were still holding these positions and locked in nice profits.

We have been unstoppable this year in the oil exploration and mining sectors. WE HAVE A HUGE GOLD PICK COMING TOMORROW NIGHT.

New featured Report NRPI

Stock Symbol :: NRPI
E-Mail this Article to a Friend
Print this Article
NRP STONE, INC (NRPI) NRP Stone, Inc. design and manufacture granite urns that can be laser–etched with a tribute to the deceased.
Recent Price $.17
Market Capitalization $45.46M
Est Float 6K
Outstanding Shares 268M
Exchange OTC.PK

NRP Stone, Inc.

950 Kipling Crescent S.W.
Redcliff, ALB T0J 2P0

Phone: 403-878-4817
Company Highlights

Similar Companies in Sector

Hillenbrand, Inc. (Hillenbrand) is the parent holding company of its wholly owned subsidiary, Batesville Services, Inc. (Batesville Casket). Through Batesville Casket, the Company is engaged in the North American death care industry where it manufactures, distributes and sells funeral service products to funeral directors who operate funeral homes. The Company’s products consist primarily of burial and cremation caskets, but also include containers and urns, selection room display fixturing for funeral homes, and other personalization and memorialization products and services, including creating and hosting websites for funeral homes. NYSE:HI Recent Price: $17.50

· Eternal Image, Inc. is engaged in the design, manufacturing and marketing of licensed brand image caskets and urns. The Company’s urns and caskets feature licensed images from Major League Baseball, Precious Moments and the Vatican Library Collection, as well as pet urns featuring the American Kennel Club and the Cat Fanciers' Association. Eternal Image urns and caskets are sold through funeral homes nationwide. OTCBB: ETNL Recent Price: $.009

Current Projects

NRP Stone Inc. Corporate Overview
NRP Stone Inc. (PINKSHEETS: NRPI) announced that the company had begun trading on the pink sheets exchange under the above symbol.
The Cremation Urn market is a relatively new market and NRP Stone Inc. has positioned itself to become a world leader in the industry. Current trends in the funeral industry cite high costs of traditional burials and the lack of space in many larger cities as the reason.

The internet has many statistics with relation to the cremation industry. Some articles claim that as many as 70% (seventy percent) of all deaths result in cremations. Some major cities are reporting figures as high as 97%.The company is in the business of providing Cremation Urns to the funeral industry and is developing both wholesale and retail outlets for its products. The company's offices are located in Redcliff, Alberta, Canada. The company plans to establish distribution centers, warehouses and sales outlets in both Canada and the United States.

Company Overview

NRP Stone, Inc. (OTC.PK: NRPI)

The company has introduced a product that will lovingly honor the memory of the dearly departed. They design and manufacture granite urns that can be laser¨Cetched with a tribute to the deceased. They are one of the first companies to offer such a product. There are many other urns available to the public, but they are not personalized to the uniqueness of the person and usually with less durable products than granite. They also plan to include other forms of memorials, such as headstones and walls as the company grows. They will endeavor to have the tribute prepared and delivered in time for the planned memorial services.

They want to ease a difficult time for many people when a loved one has passed. They will make their difficult decisions easier to handle by providing them with a meaningful tribute to the one that they have lost.

The company¡¯s goal is to become the predominate supplier of cremation urns to funeral directors and to the general public. They will do this by marketing to those in North America with the next goal, expanding into the European market.

One to 5 surfaces on the urn can be engraved. All the customer has to do is provide images of their loved one with personal photos, email photos, or they may choose one of our available designs. They laser the image onto the finest black granite. A singe image or a composite, all are done in a timely manner. This becomes a lasting memory at a reasonable cost.

The company believes that people in the state of grief have many difficult decisions to make and they want to ease their decision making efforts. They want to provide them with a quality product that will symbolize the love that they shared with the deceased.

They are in the memorial industry which will be undergoing a crucial change in the near future. As the population grows and the residents succumb to life¡¯s many challenges, cemetery space is in demand and thus the cost has become premium. NRP Stone is in a position to help maintain burial land while providing the bereaved with a beautiful memorial to their loved ones. Their business is the first to incorporate new techniques in providing this service.

Their strengths lie in the quality of our product and with our management team who provide many years of experience to this organization. The company vice-president has been in the memorial business since 1969 and has witnessed the many changes that funeral directors and the bereaved have had to endure.

With an increasing aging population, mortality numbers are on a constant increase. The planet will be unable to handle the burial of millions upon millions of people; therefore, they must look to other methods of handling the deceased without infringing upon the emotions of those grieving. One option to be considered is cremation. At the moment, cremations performed in the lesser populated states are fairly low while in the more populated states cremation is the norm. This is due to the lack of burial space available to citizens of large cities. Those that are adamant about traditional burials are paying an ever increasing price for the privilege. Cremation numbers are increasing and will continue to increase. Cremation is an economical solution to both the lack of burial space and the ever increasing costs of burial.

NRP Stone Inc. has introduced a product that will lovingly honor the memory of the dearly departed. They design and manufacture granite urns that can be laser¨Cetched with a tribute to the deceased. They are one of the first companies to offer such a product. There are many other urns available to the public, but they are not personalized to the uniqueness of the person and usually with less durable products than granite. They also plan to include other forms of memorials, such as headstones and walls as the company grows. They will endeavor to have the tribute prepared and delivered in time for the planned memorial services.

Alberta and Northern British Columbia are only the first step in an International marketing strategy. They are setting up distribution and engraving centers in Florida, Tennessee and California. As soon as resources and training of staff permit they will be opening more centers where they will be better able to service their customers.

Urn Dimensions

Deluxe Urns
Length ¨C 11.5¡å
Height ¨C 7¡å
Width ¨C 6¡å
Weight ¨C 15lbs

Cubic Urns
Length ¨C 9¡å
Height ¨C 8¡å
Width ¨C 4¡å
Weight ¨C 13lbs

Speciality Urns

NRP Stone can make almost any design or urn the customer desires. One example is a speciality urn that was made for a rancher and which is mounted on a fence post at the entrance to his ranch. The roof is green, the walls are red, and the base is black granite. Since the words on any color except for black are very hard to see using the laser technique, they used sandblasting for the text.

Speciality urn pricing is subject to the design.

Ordering & Pricing

They willprovide to their customers, urns created from the finest black granite that they can obtain throughout the world.They engrave these urns with pictures and/or phrases that have special meaning both to the deceased and the bereaved. The customer can provide their own selection of photos or they may choose from the many designs that the company has on hand. They are able to reproduce a good quality photo almost down to the eyelashes, so what is seen in the photo is seen on the urn, only in shades of black and white.

They will be able to provide this service to the customer on a priority basis, thus they will have the product delivered to them in just a few days. The amount of time before shipping will depend upon the clarity of the image that the customer provides and approves. They expect to have the urn in the customer¡¯s hand within a few days. If the customer contacts us through the funeral director they should have the urn in their hands before the memorial service.

Price List

Deluxe or Cubic Urn ¨C $375.00

Engravings for each face which includes up to 2 images and text ¨C $40.00

Additional images per face ¨C $40.00

Prices do not include shipping, handling, and taxes.

Another Sign Of The Recession ¡ª Cremation On The Rise

The recession has forced consumers to cut back on spending in almost every area of life. Now death, it seems, is no exception. The funeral industry is changing to accommodate budget-conscious families and the number of cremations is on the rise.

"These are tough economic times," said National Funeral Directors Association (NFDA) spokesperson Jessica Koth, "and what we are hearing from our members is that more and more families are opting for cremation" as a low-cost alternative to a traditional burial.

It's not the service or the casket that breaks the bank, Koth said. According to NFDA's data, the average funeral package (with a casketed service and a burial) costs $4,277. A casketed service and cremation costs slightly less, about $4,054. The issue is that these packages don't include the grave, which can practically double the cost of a funeral.

LEADERSHIP Richard G. Blum, Dir.
Pearl B. Davy, Dir.
Norman J. Davy, President, Treasurer, Secretary, Dir.


Tuesday, August 25, 2009

9 Stocks With Sustainable Dividends For The Long Run



Dividend Yield


Div Payout Ratio


Abbot Laboratories



53% - close enough


Dover Corp





Emerson Electric





Johnson & Johnson








53% - close enough


McGraw-Hill Corp





Procter & Gamble





Stanley Works





VF Corp




MDXO,TMR,VG-Watch List for Tuesday 8-25-2009

MDXO - News
Midex Gold Corp., management announced today that, effective August 13, 2009, the Company entered into an Agreement with Douglas Lake Minerals Inc. ("Douglas Lake") on the Magembe diamond property in the Shinyanga district of Tanzania. The Magembe diamond property consists of 46 square kilometers directly adjacent to the eastern, northern, and western boundaries of the Williamson (Mwadui) Mine, the world's largest diamond pipe and one of Africa's most prolific diamond producers.


TMR - Momentum
The Meridian Resource Corporation, together with its subsidiaries, explores for, acquires, develops, and produces oil and natural gas reserves, primarily located onshore in south Louisiana and Texas; and offshore in the Gulf of Mexico.


VG - Volume Alert
Vonage Holdings Corp., through its subsidiaries, provides broadband Voice over Internet Protocol services to residential and small business and home office customers.

MDXO,LEARQ,ARSC-Watch List for Tuesday 8-25-2009

MDXO - News Alert
Midex Gold Announces Finalizing Agreement With Douglas Lake Minerals on Magembe Diamond Property

LEARQ - Volume Alert
Lear Corporation designs, manufactures, and markets automotive seat systems, electrical distribution systems, and electronic products for the automotive industry.

ARSC - Trade Alert
American Security Resources Corporation, through its subsidiaries, focuses on the development and commercialization of hydrogen fuel cells and related clean energy technologies.

IMMEDIATE BUY: Ventana Biotech (VNTA)

Ventana Biotech (VNTA) is rocking the anti-obesity segment of the health care industry with news of a chewing gum that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not.
Royalty cash flow from an anti-obesity drug is estimated at $1.5 to $1.7 billion a year.
Holding the key to this billion-dollar medical breakthrough is a young, under-the-radar biotech in England, Ventana Biotech. Trading symbol VNTA.

Imagine the buying frenzy created by a chewing gum that makes you thin.
Better yet, imagine the money you can make when you're one of the select individual investors able to get in early on the biotech stock making it happen.
Ventana Biotech's secret is found in the targeted hormonal triggers that are released with every chew... they tell your body you're full, even when you're not.
Practically everyone I know would run through a brick wall to get their hands on Ventana's product -- millions of us want lose weight. Unfortunately, millions more MUST lose weight, or die.

I'll bet you or someone you know has a friend who is either seriously overweight and in serious health danger, or clinically obese and in immediate health danger.

Well, your friends are not alone.

Obesity in America is epidemic. As many as 192 million Americans (about 66% of the population) are seriously overweight... clinically obese... and worse.

Obesity no longer waits for its victims to reach middle age. The disease is infecting children now -- at alarming rates.

Obesity kills -- more than 377,000 Americans were buried last year as a direct result of obesity. But health care professions know that obesity is far more deadlier than that.

Obesity leads the way to diabetes (more about that in a moment), and a long list of conditions that all lead to fatal heart disease.

And it's not just here in America. What's causing obesity's pandemic spread is a story better told another day. This report is for individual investors interested in the profits promised by effective treatments.

The only thing that gets fat is your wallet

Buy Ventana Biotech. This is a young company in England on the verge of grabbing a giant share of the $60-billion devoted to obesity, or I should say, devoted to eliminating
The trading symbol is VNTA.
The money you can make buying this stock today could change your life. Here's how...

Ventana Biotech is rocking the anti-obesity industry with news of a chewing gum -- yes, chewing gum -- that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not.

Pre-trial testing for FDA approval is now getting into gear.
Buy VNTA now!

The first commercial application of the "targeted hormonal triggers" to hit the market will likely be injectable and administered by doctors. This alone would be enough to lift VNTA shares to soaring heights.

Ventana Biotech could be hauling in anywhere from $1.5 to $1.7 billion on this obesity treatment.

There's more.

The company's proprietary flagship product will treat not just obesity but also could treat Type-II diabetes.
Even more amazing than this medical breakthrough is the amount of money you can make buying VNTA shares today. A modest $5,000 buy could balloon to $45,000 or more inside a year. Those who buy now stand to make the most money.
  • Big pharma is dying to get its hands on this ground breaking anti-obesity treatment -- because billions of dollars are at stake.

  • News of the royalty cash flow set to flood Ventana Biotech -- estimated at $1.5 to $1.7 billion
    -- can quickly TRIPLE the value of this still young $37 million company.

  • Ventana Biotech conducts R&D without burning through cash, virtually eliminating financial risk to the company and its shareholders

  • Ventana's miracle treatment works its magic without subjecting patients to dangerous side effects or adverse reactions... a welcome relief for patients and healthcare professionals alike.

  • And now this revolutionary anti-obesity breakthrough is also being studied as a treatment for patients with Type II diabetes
Morgan Stanely
estimates the market
for drugs combating
Type II diabetes
to be in excess of
$35 billion by 2012.

Put Ventana Biotech in your portfolio right now. You can get it for under a buck. I'm telling readers to buy up to $3.00 for awesome profits.

I'm telling you to buy VNTA today so you can make a fast TRIPLE BEFORE we even reach the buy limit.

If you've been following stocks -- particularly biotech stocks -- then you know new drugs and speculation surrounding them can often move stocks by huge percentages in a single trading session.

Beat Wall Street
to Massive Profits

Ventana Biotech is such a young company ($37 million market cap), and since it is in England (but traded publicly here in the US under the symbol VNTA), the company is off Wall Street's radar screens. Most investors don't even know this blockbuster exists.

Driving Ventana -- and your investment profits -- is the company's proposed Anti-Obesity Chewing Gum (it doesn't have a fancy brand name yet).

Early indications show the Gum safely reduces appetite by 15% to 25% and Ventana continues to perfect their biotechnology.

Royalty cash flow in the billions

Pre-trial testing for FDA approval is getting into gear -- and exclusive licensing of the product to Big Pharma is just around the corner.

Royalty cash flow from a successful anti-obesity drug is conservatively estimated at $1.5 to $1.7 billion a year. That's big money for any company. For a company the size of Ventana Biotech, the money is huge.

And there's more.

Once approved in the US by the FDA, Ventana's anti-obesity chewing gum will be included among 10 other competing oral therapies for diabetes as well.

FDA approval seems a lock since Ventana's proprietary product is entirely safe.* It contains an extract of hoodia gordonii and 2-hydroxyoleic acid.
* Please note that this product has not been approved by the FDA.

Hoodia gordonii is a leafless, catus-like plant that grows wild in Southern Africa. Native populations used the plant for hundreds of years to suppress appetite on long hunting trips in the Kalahari Desert.

Now modern science discovers the plant also possesses the ability to lower blood glucose levels, thereby also thrusting Ventana Biotech's anti-obesity product into the limelight for treatment and prevention of diabetes as well.

But first, you stand to make a fortune defeating obesity.

Here's how the miracle works

The active ingredients in the plant extracts are released into the patient's blood stream and trigger a hormonal response in the part of the brain (the hypothalamus) that tells you, "I'm full."

And because the plant extracts activate a hormone that naturally exists in the body -- it's naturally produced every time you finish a meal -- there are no harmful side effects.
Buy VNTA now -- get in under a buck!

Ventana Biotech belongs in your portfolio right now. You can get shares for under a buck. I'm telling readers to buy up to $3.00 for awesome profits. I'm telling you to get VNTA today so you can make a fast TRIPLE BEFORE we even reach the buy limit.

A modest $5,000 investment in VNTA looks to zoom to $19,230 -- before the stock climbs to my $3 buy limit... then to $23,076 when the buy target is meet... and then from there, onwards and upwards even higher.
I expect you'll make so much money on VNTA alone that you'll want regular profit alerts from me as a subscriber to my newsletter.
Each year I put out a Winning Stocks Report and since 2004, clients who bought the stocks absolutely trounced the market.

You might also be interested to know since 2004, clients who bought the stocks I recommended in my annual Winning Stocks special report absolutely trounced the market. In 2007, for example our Winning Stock recommendations ended the year with a stunning 51.8%---a huge win when you consider the Dow was up only 6.4%

  • Wentworth Energy
  • Suncor Energy
  • Genzyme
  • Pharma Product Dev
  • +1,000%
  • Nova Gold
  • Advanced PSC
  • Petro China
  • U.S. Global
  • +135%

    HEPI.OB Reports Safety Findings, Extends PAZ Study

    Tuesday, 25 August 2009 05:04

    Health Enhancement Products, Inc. (OTC:HEPI) (HEPI.OB) is a nutraceutical company engaged in the development of dietary supplements, food additives, and ingredients which are created entirely from pure, all-natural compounds. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water through a process whereby the water in which the algae is gro Diggwn is drawn off, filtered, and bottled as PAZ (now marketed with a new name and look as LiquidMD).

    On 7/15/09, HEPI.OB announced preliminary results of its study to confirm the efficacy of its PAZ bioactive compound in managing LDL and HDL cholesterol levels. The WSU study confirmed that the PAZ organic compound was found to reduce LDL (bad) cholesterol levels from 131.7mg/dL to 79.57mg/dL and improve HDL (good) cholesterol from 105.27mg/dL to 138.67mg/dL in test animals (hamsters).

    On 8/25/09, HEPI.OB (in conjunction with Wayne State University, WSU) announced that the WSU research team, led by Smiti Gupta, Ph.D., assistant professor of Nutrition & Food Sciences noted the absence of any detectable inflammation in liver samples taken from the test subjects in its preliminary study findings. This is encouraging, given that other means of controlling cholesterol such as multi-billion dollar selling statin drugs (e.g. Lipitor, Zocor, Crestor) may have a negative effect on liver function.

    As a result of positive results obtained thus far, the Company announced the expansion of the current WSU study, adding a therapeutic component to the study to establish the efficacy of specific, isolated PAZ filtrates in managing cholesterol and inflammation over a longer period of time, as well as a review of toxicity, safety and dosing parameters and HEPI expects to provide an update on this process in the coming weeks (with a 9/21/09 estimate for this entry).

    Click here for my overview article on HEPI from early August and below is an outline of upcoming catalysts and milestones that I expect to occur over the near to intermediate term (a few weeks to six months):

    (1) updates from the expanded WSU study to provide longer term data on the Company's isolated PAZ filtrates in managing cholesterol and inflammation, as well as a review of toxicity, safety and dosing parameters

    (2) the publication of a scientific paper derived from the extended WSU study findings by Dr. Gupta

    (3) the isolation and identification of the bioactive molecule(s) in PAZ as part of the extended WSU study

    (4) the announcement of a global licensing deal with a major packaged food company such as GIS, K, KFT, or Nestle to created functional food products such as cereals that contain the bioactive molecule(s) isolated from PAZ once longer term safety and efficacy data is obtained from human studies.

    Filing wih the SEC Makes Cel-Sci's Plans Look Even More Enticing to Investors

    Tuesday, 25 August 2009 02:27

    Shares of CEL-SCI continue to tick upward as signs point to a resurection of sorts for this biotech play that many had on the ropes and ready for a knock-out punch.

    This was a company struggling to keep their doors open before a recent influx of millions in bullish investment capital and recent debt pay-offs.

    Once can see trading volume increasing as speculators have begun to move in now that the most recent filings with the SEC have confirmed that CEL-SCI has also been quietly positioning itself as a player in the H1N1 space with solutions that will get the attention of parties at the CDC, FDA and beyond (if they haven't already). This possibility now ringing more true than ever given the warning bells sounded by the Obama administration's advisory group on Science and Technology, who said in a report released yesterday afternoon that the H1N1 flu virus could cause as many as 30,000 and 90,000 deaths in the United States and that it "poses a serious health threat" to young people and children- unlike past strains of the virus.

    The widely published report predicts that at least 1.8 million people will be hospitalized during the epidemic, with up to 300,000 patients requiring intensive care units. These patients could occupy 50-100 percent of all ICU beds in affected regions at the peak of the epidemic and would place "enormous stress" on ICU units.

    Keep in mind that these are U.S. numbers alone and that this is one of the few countries with the financial resources to begin "hording" vaccine suuplies. Imagine what the impact might be in coutries with far, far fewer resources.

    From a trading standpoint, one need only look at the recent run ups by "small" companies like Novavax, Inc. (NasdaqGM:NVAX), BioCryst Pharmaceuticals Inc. (Nasdaq:BCRX), and Generex Biotechnology (Nasdaq:GNBT) to realize that speculative buyers have not only been turning the increasingly bad news into a Swine Flu Bonanza. Look at what those stocks were trading at back in March and realize that it only gets more interesting from here.

    And so, day after day, we see press releases from companies attempting to position themselves as players in this space. Still, few have offered solutions that prove substantive after a close look under the microscope, both figuratively and literally.

    By contrast, CEL-SCI has become tantalizingly alluring because they have kept their head down, busily preparing both in the lab and via back channels in Washington- at least according to some sources at our nations capital, interestingly, not far from where CEL-SCI is headquartered.

    When I first approached them for comments after stumbling across them while doing research for my investigative article about H1N1 they said only enough as was required. Now, more details have emerged about the rumored flu vaccine and treatment I first told our subscribers about over the weekend. Although the details were very sketchy when we interviewed the company CEO, Geert Kersten on Friday, we have now pieced together more information about their innovative, dare I say revolutionary, approach to dealing with the growing flu problem.

    The latest filing with the SEC confirms, that CEL-SCI has created one (and perhaps even several) potential peptide vaccine/treatments against H1N1 swine flu using their L.E.A.P.S.™ technology- a patented, T-cell modulation, peptide epitope delivery technology. The platform has enabled CEL-SCI to begin pre-clinical formulation, evaluation and testing of a new application of its H1N1 vaccine, which will allow the targeting of "mutated" versions of H1N1 swine and other influenza viruses. World health officials believe that the influenza virus may mutate and evolve between now and the winter flu season.

    According to the filing:

    "In conjunction with the testing, CEL-SCI has produced several L.E.A.P.S. flu vaccines that focus on the conserved, non changing epitopes of the different strains of Type A Influenza viruses (H1N1,H5N1, H3N1, etc.), including "swine", "avian or bird", and "Spanish Influenza", in order to minimize the change of viral "escape by mutations" from immune recognition. CEL-SCI's L.E.A.P.S. flu vaccine contains epitopes known to be associated with immune protection against influenza in animal models."

    This is a developing story. As we mentioned earlier we have scheduled an interview with the company CEO, who was not available for immediate comment.

    It is known, however that administered like vaccines, LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases (the company has disclosed that they are also working on a potential rheumatoid arthritis vaccine).

    "The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body's selection of the 'inappropriate' immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and
    drugs in attacking an underlying disease."

    Also according to the filing, CEL-SCI also discovered a second peptide named CEL-2000.

    "The data from animal studies of rheumatoid arthritis using the CEL-2000 treatment vaccine demonstrated that CEL-2000 is an effective treatment against arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments, including Enbrel(R). CEL-2000 is also potentially a more disease type specific therapy, is calculated to be significantly less expensive and may be useful in patients unable to tolerate or who may not be responsive to existing anti-arthritis therapies."

    New details have begun to emerge about Cel-Sci Corporation's (Amex:CVM) new new, state-of-the-art "Cold-Fill" manufacturing facility which will not only be used to manufacture Multikine® the world's first immunotherapeutic agent (which is being developed as a first-line standard of care treatment for cancer) for both the Phase III trials and commercial sales, but CEL-SCI plans to offer the use of the facility as a service to pharmaceutical companies and others, particularly those that need to "fill and finish" their drugs in a cold environment (4 degrees Celsius, or approximately 39 degrees Fahrenheit).

    This is a key process of filling injectable drugs in a sterile manner and is an important part of the manufacturing process for many medicines.

    This lab, which many now consider a cornerstone to the future financial success of the company is located near Baltimore, MD. According to newly released documents filed with the SEC, it was designed over several years, and was built out to CEL-SCI's specifications during the past 18 months.

    One insider calls it "absolutely state-of-the art" and "extremely impressive down to the smallest screw."

    An interview between CEL-SCI's CEO, Geert Kersten, has been scheduled and more details will follow in this space as soon as I can provide them, but CEL-SCI believes it will be able to charge approximately $150,000 for an eight hour fill and finish "run" at this extremely unique facility whose aseptic filling suites are maintained at FDA and EU ISO classifications of 5/6. CEL-SCI also has the capability to formulate,
    inspect, label and package biologic products at cold temperatures. Furthermore, the company discloses that they do not know of any other facility in the United States which is able to provide cold 4 degrees Celsius finish and fill services on a contract basis.

    What this will mean for the financial security and future of the company is significant, particularly given the fact that the fastest area of growth in the biopharmaceutical and pharmaceutical markets is biologics, and most recently stem cell products. These compounds and
    therapies are derived from or mimic human cells or proteins and other molecules. Nearly all of the major drugs developed for unmet medical needs (e.g., Avastin(R), Erbitux(R), Rituxan(R), Herceptin(R), Copaxon(R), etc.) are biologics. Biologics are usually very sensitive to such things as heat and humidty and are known to quickly lose their biological activity if exposed to room or elevated temperatures (which may also affect the shelf-life of a biologic- with the result being that the product cannot be stored for as long as desired).

    These products do not generally lose activity when kept at 4 degrees Celsius.